Phase 2 N=37 Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199
Asthma · Airway Obstruction
Primary: FEV1 Peak Effect Within 0 - 24 h Post-dose — 3.56; 3.62; 3.70; 3.62 L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours
Epilepsy
Primary: Assessment of Taste Preference — 5.8; 5.8; 7.1 units on a scale (0-10 cm VAS)
Phase 2 N=71 Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Relapse-free Survival — 48 participants
Phase 2 N=16 An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins
Varicose Veins
Primary: Responders to Treatment, Assessed by Duplex Ultrasound — 9 participants
Phase 2 N=42 Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Pancreatic Cancer · Ductal Adrenocarcinoma · Exocrine Pancreatic Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 8; 18; 16 participants
Phase 2 N=40 PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Prostate Neoplasms
Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…
Phase 2 N=57 Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide
Malignant Glioma
Primary: Safety and Tolerability of Palonosetron as Determined by the Number of Participants Who Experience Unacceptable Toxicity — 5 participants
Phase 2 N=154 Study of Phosphate Levels in Patients With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change From Baseline in Serum-phosphate Levels at the End of Treatment. — -0.042; -0.348; -0.404; -0.644 mmol/L
Phase 2 N=103 Bortezomib in Treating Patients With Lymphoproliferative Disorders
Recurrent Grade 1 Follicular Lymphoma · Recurrent Grade 2 Follicular Lymphoma · Recurrent Grade 3 Follicular Lymphoma
Primary: Response Rate — 11; 6 participants
Phase 2 N=6 Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)
Alternating Hemiplegia of Childhood
Primary: Time Duration of AHC Episodes
Phase 2 N=16 Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Idiopathic Solar Urticaria
Primary: Assessment of the Minimal Urticaria Dose (MUD) on Each Test Site, After Application of the Test Products — 4.33; 3.93; 3.80; 3.67 Photodermatosis Protection Factor
Phase 2 N=20 A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
Alcohol Dependence
Primary: Number of Very Heavy Drinking Days Per Week — 2.1; 1.3 days
Phase 2 N=175 GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With Overall Response At the End of Induction Period — 33.3; 44.6 Percentage of participants — p=0.1587
Phase 2 N=35 Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Leukemia · Lymphoma · Myelodysplastic Syndrome
Primary: The Cumulative Incidence of Grade II-IV Acute GVHD up to Day 100 After Stem Cell Infusion — 32 Percentage of participants
Phase 2 N=204 T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Acute Myelogenous Leukemia · Lymphoid Leukemia · Chronic Myelogenous Leukemia
Primary: Median Disease-free Survival — 333 Days